Drug therapy may effectively treat a potentially life-threatening condition associated with cirrhosis and other chronic liver diseases, according to a new study by Mayo Clinic researchers. The study was posted in March on Gastroenterology, the online journal of the American Gastroenterological Association. Print publication is scheduled for July.
While therapies have been available to treat some forms of liver disease, including hepatitis C and autoimmune hepatitis, options have been more limited for treating portal hypertension, a condition where there is an increase in pressure within the portal vein that carries blood from abdominal organs to the liver. Portal hypertension is associated with cirrhosis and other chronic liver diseases.
According to the study, the drug sivelestat may effectively lower portal hypertension, improving symptoms and outcomes for those patients. The study results were obtained from mouse models but have since been confirmed in liver samples from humans, according to Vijay Shah, M.D., a Mayo Clinic gastroenterologist and senior author.
“This was an exciting confirmation of our findings and their applicability to human disease,” Dr. Shah says. “Sivelestat has been safely used in humans with acute lung injury and bronchopulmonary dysplasia. This suggests that sivelestat and similar drugs constitute a potential means to decrease portal hypertension in patients with chronic liver disease.”
The Mayo study showed that deposits of fibrin — microvascular blood clots — contributed to portal hypertension, and inflammatory cells known as neutrophils contributed to the formation of fibrin. By inhibiting neutrophil function with sivelestat, they were able to decrease portal hypertension.
“Neutrophils had not previously been identified as significant drivers of portal hypertension,” says Moira Hilscher, M.D., the paper’s first author. Results were verified in two different models of chronic liver disease.
“The study paves the way for developing new drugs and repurposing of existing compounds to target inflammation in the liver driven by disease-related mechanical forces,” says Dr. Hilscher. “Given the increasing prevalence of advanced liver disease due to alcohol and obesity, this is clearly an unmet need.”
Learn more: Mayo Clinic researchers identify potential new therapy for liver diseases
The Latest on: Liver diseases
[google_news title=”” keyword=”liver diseases” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Liver diseases
- Risk of liver fluke and black disease following wet springon April 27, 2024 at 8:59 am
Unseasonal wet weather is not only increasing the risk of liver fluke but it is also pre-disposing cattle to black disease. That was the stark warning from Dr Kat Baxter-Smith, veterinary adviser with ...
- Black Unsweetened Coffee For Fatty Liver Disease: Understanding How The Two Are Relatedon April 27, 2024 at 6:46 am
Then this article is for you. Studies published in the Journals Cleveland Clinic Health Essentials and WebMD states that, unsweetened black coffee may help with fatty liver diseases and ease some of ...
- Metabolic Dysfunction-Associated Steatotic Liver Disease Plus HIV Ups Risk for CVD but Not Liver Diseaseon April 25, 2024 at 10:47 pm
A large study reveals an increased risk for adverse cardiovascular events but not for liver disease progression in adults with MASLD disease and HIV infection.
- Baseline Enrollment Completed for AMRA Medical and Linköping University's Landmark Liver Disease Studyon April 25, 2024 at 4:57 am
AMRA Medical, a health informatics and precision medicine company that is pioneering body composition research through gold-standard MRI-based analysis platforms, in collaboration with Linköping ...
- Researchers discover biology behind Fontan-operation-associated liver diseaseon April 24, 2024 at 11:00 am
As patients with congenital heart diseases live longer, researchers are attempting to understand some of the other complications they may face as they age. A team from Children's Hospital of ...
- Carbon beads may help reduce liver disease, restore gut healthon April 23, 2024 at 1:00 am
New research shows that innovative carbon beads — which are capable of absorbing harmful bacteria and toxins — could improve gut health, and reduce the progression of liver disease.
- Boehringer Ingelheim, Ochre Bio Launch Up-to-$1B+ Liver Disease Partnershipon April 22, 2024 at 12:48 pm
Boehringer Ingelheim will apply Ochre Bio’s discovery platform to develop treatments for late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and other chronic liver diseases ...
- Rising rates of fatty liver disease in young adultson April 17, 2024 at 7:32 am
Recent health research has revealed alarming trends in the prevalence of fatty liver disease among young adults ...
- Fatty liver disease affecting one in five young adults, Bristol study showson April 16, 2024 at 10:09 pm
One in five young adults has evidence of fatty liver disease, according to new health research. Fatty liver disease, mainly caused by alcohol and obesity, traditionally affects people in their 40s to ...
- Coffee & Coconut Creamer: What Patients With Fatty Liver Disease Should Know (Curated by Nutrition Professionals).on April 16, 2024 at 2:28 pm
This article examines the potential benefits of adding coffee with coconut creamer to the diet of those with fatty liver disease. Expert opinions from three professionals in the fields of health and ...
via Bing News